Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Abuse potential of mirogabalin in recreational polydrug users.

Mendell J, Levy-Cooperman N, Sellers E, Vince B, Kelsh D, Lee J, Warren V, Zahir H.

Ther Adv Drug Saf. 2019 Apr 5;10:2042098619836032. doi: 10.1177/2042098619836032. eCollection 2019.

2.

Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.

Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K.

Epilepsy Behav. 2018 Nov;88:162-171. doi: 10.1016/j.yebeh.2018.07.027. Epub 2018 Oct 2.

3.

Pharmacokinetic and Pharmacodynamic Correlations From 2 Studies Evaluating Abuse Potential of Hydrocodone Extended-Release Tablets.

Schoedel KA, Gillespie M, Levy-Cooperman N, Shram MJ, Rabinovich-Guilatt L.

Clin Pharmacol Drug Dev. 2019 Jan;8(1):32-39. doi: 10.1002/cpdd.468. Epub 2018 May 3.

PMID:
29723441
4.

Evaluating the abuse potential of opioids and abuse-deterrent -opioid formulations: A review of clinical study methodology.

Setnik B, Schoedel KA, Levy-Cooperman N, Shram M, Pixton GC, Roland CL.

J Opioid Manag. 2017 Nov/Dec;13(6):485-523. doi: 10.5055/jom.2017.0412. Review.

PMID:
29308594
5.

Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.

Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, Coe MA, Jones JD, Nuzzo PA, Tiberg F, Sheldon B, Kim S.

JAMA Psychiatry. 2017 Sep 1;74(9):894-902. doi: 10.1001/jamapsychiatry.2017.1874.

6.

Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER).

Kopecky EA, Fleming AB, Levy-Cooperman N, O'Connor M, M Sellers E.

J Clin Pharmacol. 2017 Apr;57(4):500-512. doi: 10.1002/jcph.833. Epub 2016 Nov 1.

7.

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.

Harris SC, Cipriano A, Colucci SV, Kapil RP, Geoffroy P, Hopyan T, Levy-Cooperman N.

Pain Med. 2017 Jul 1;18(7):1278-1291. doi: 10.1093/pm/pnw208.

8.

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.

Levy-Cooperman N, McIntyre G, Bonifacio L, McDonnell M, Davenport JM, Covington PS, Dove LS, Sellers EM.

J Pharmacol Exp Ther. 2016 Dec;359(3):471-481. Epub 2016 Sep 19.

9.

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.

Setnik B, Bass A, Bramson C, Levy-Cooperman N, Malhotra B, Matschke K, Geoffroy P, Sommerville KW, Wolfram G.

Pain Med. 2017 Jun 1;18(6):1077-1088. doi: 10.1093/pm/pnw178.

10.

Abuse deterrence testing: A dose ratio escalation study examining naloxone coadministered with intravenous hydromorphone in non-treatment-seeking, opioid-dependent drug users.

Levy-Cooperman N, Schoedel KA, Reiz JL, Thompson D, Chakaraborty B, Geoffroy P, Michalko KJ.

J Opioid Manag. 2016 May-Jun;12(3):165-80. doi: 10.5055/jom.2016.0329.

PMID:
27435437
11.

Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial.

Levy-Cooperman N, Schoedel KA, Chakraborty B, Blum D, Cheng H.

Epilepsy Behav. 2016 Aug;61:63-71. doi: 10.1016/j.yebeh.2016.05.010. Epub 2016 Jun 15.

12.

Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.

Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA.

J Clin Psychopharmacol. 2016 Aug;36(4):314-23. doi: 10.1097/JCP.0000000000000516.

PMID:
27253658
13.

Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.

Harris SC, Cipriano A, Colucci SV, Kapil RP, Geoffroy P, Hopyan T, Levy-Cooperman N.

Pain Med. 2016 May;17(5):820-31. doi: 10.1093/pm/pnv004. Epub 2015 Dec 14.

14.

Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users.

Koblan KS, Hopkins SC, Sarma K, Gallina N, Jin F, Levy-Cooperman N, Schoedel KA, Loebel A.

Drug Alcohol Depend. 2016 Feb 1;159:26-34. doi: 10.1016/j.drugalcdep.2015.10.029. Epub 2015 Dec 3.

15.

Self-reports of prescription opioid abuse and diversion among recreational opioid users in a Canadian and a United States city.

Setnik B, Roland CL, Goli V, Pixton GC, Levy-Cooperman N, Smith I, Webster L.

J Opioid Manag. 2015 Nov-Dec;11(6):463-73. doi: 10.5055/jom.2015.0299.

PMID:
26728643
16.

Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.

Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB.

Pain Med. 2015 Nov;16(11):2142-51. doi: 10.1111/pme.12834. Epub 2015 Jun 22.

PMID:
26108255
17.

Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.

Setnik B, Bramson C, Bass A, Levy-Cooperman N, Malhotra B, Matschke K, Sommerville KW, Wolfram G, Geoffroy P.

J Clin Pharmacol. 2015 Dec;55(12):1351-61. doi: 10.1002/jcph.552. Epub 2015 Jul 2.

PMID:
26011742
18.

Brain Network Activation (BNA) reveals scopolamine-induced impairment of visual working memory.

Reches A, Levy-Cooperman N, Laufer I, Shani-Hershkovitch R, Ziv K, Kerem D, Gal N, Stern Y, Cukierman G, Romach MK, Sellers EM, Geva AB.

J Mol Neurosci. 2014 Sep;54(1):59-70. doi: 10.1007/s12031-014-0250-6. Epub 2014 Feb 18.

PMID:
24535560
19.

Estradiol and mental rotation: relation to dimensionality, difficulty, or angular disparity?

Hampson E, Levy-Cooperman N, Korman JM.

Horm Behav. 2014 Mar;65(3):238-48. doi: 10.1016/j.yhbeh.2013.12.016. Epub 2014 Jan 4.

PMID:
24394702
21.

Lesion Explorer: a comprehensive segmentation and parcellation package to obtain regional volumetrics for subcortical hyperintensities and intracranial tissue.

Ramirez J, Gibson E, Quddus A, Lobaugh NJ, Feinstein A, Levine B, Scott CJ, Levy-Cooperman N, Gao FQ, Black SE.

Neuroimage. 2011 Jan 15;54(2):963-73. doi: 10.1016/j.neuroimage.2010.09.013. Epub 2010 Sep 19.

PMID:
20849961
22.

Functional correlates of instrumental activities of daily living in mild Alzheimer's disease.

Nadkarni NK, Levy-Cooperman N, Black SE.

Neurobiol Aging. 2012 Jan;33(1):53-60. doi: 10.1016/j.neurobiolaging.2010.02.001. Epub 2010 Mar 31.

23.

Frontal lobe hypoperfusion and depressive symptoms in Alzheimer disease.

Levy-Cooperman N, Burhan AM, Rafi-Tari S, Kusano M, Ramirez J, Caldwell C, Black SE.

J Psychiatry Neurosci. 2008 May;33(3):218-26.

24.

Misclassified tissue volumes in Alzheimer disease patients with white matter hyperintensities: importance of lesion segmentation procedures for volumetric analysis.

Levy-Cooperman N, Ramirez J, Lobaugh NJ, Black SE.

Stroke. 2008 Apr;39(4):1134-41. doi: 10.1161/STROKEAHA.107.498196. Epub 2008 Mar 6.

PMID:
18323507
25.

Subcortical hyperintensities in Alzheimer's disease: no clear relationship with executive function and frontal perfusion on SPECT.

Levy-Cooperman N, Lobaugh NJ, Caldwell C, Gao F, Black SE.

Dement Geriatr Cogn Disord. 2007;24(5):380-8. Epub 2007 Oct 11.

PMID:
17934273

Supplemental Content

Loading ...
Support Center